In addition, Xu et al. showed that miR-133b could alleviate glioma development via repressing the Wnt/β-catenin signaling pathway by inhibiting EZH2, which provides a potential treatment biomarker for glioma [48]. This evidence concerns the gene EZH2 and glioma.